0001209191-21-007906.txt : 20210204
0001209191-21-007906.hdr.sgml : 20210204
20210204195803
ACCESSION NUMBER: 0001209191-21-007906
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210202
FILED AS OF DATE: 20210204
DATE AS OF CHANGE: 20210204
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: STACK DAVID M
CENTRAL INDEX KEY: 0001204788
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35060
FILM NUMBER: 21592877
MAIL ADDRESS:
STREET 1: THE MEDICINES CO
STREET 2: 8 CAMPUS DRIVE
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Pacira BioSciences, Inc.
CENTRAL INDEX KEY: 0001396814
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 510619477
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5 SYLVAN WAY
STREET 2: SUITE 300
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
BUSINESS PHONE: 973-254-3560
MAIL ADDRESS:
STREET 1: 5 SYLVAN WAY
STREET 2: SUITE 300
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
FORMER COMPANY:
FORMER CONFORMED NAME: Pacira Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20101029
FORMER COMPANY:
FORMER CONFORMED NAME: PACIRA INC
DATE OF NAME CHANGE: 20080318
FORMER COMPANY:
FORMER CONFORMED NAME: Blue Acquisition Corp
DATE OF NAME CHANGE: 20070418
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-02-02
0
0001396814
Pacira BioSciences, Inc.
PCRX
0001204788
STACK DAVID M
C/O PACIRA BIOSCIENCES, INC.
5 SYLVAN WAY, SUITE 300
PARSIPPANY
NJ
07054
1
1
0
0
CEO and Chairman
Common Stock
2021-02-02
4
M
0
21250
10.81
A
97311
D
Common Stock
2021-02-02
4
S
0
2900
68.41
D
94411
D
Common Stock
2021-02-02
4
S
0
14250
69.38
D
80161
D
Common Stock
2021-02-02
4
S
0
4100
70.20
D
76061
D
Common Stock
2021-02-03
4
M
0
21250
10.81
A
97311
D
Common Stock
2021-02-03
4
S
0
6900
70.78
D
90411
D
Common Stock
2021-02-03
4
S
0
14350
71.42
D
76061
D
Common Stock
98353
I
By Three Colleens Investment, LLC
Common Stock
18596
I
By Stack Schroon Mohawk FLP
Common Stock
315
I
By LCK Investment LLC
Stock Option (Right to Buy)
10.81
2021-02-02
4
M
0
21250
0.00
D
2022-06-05
Common Stock
21250
152420
D
Stock Option (Right to Buy)
10.81
2021-02-03
4
M
0
21250
0.00
D
2022-06-05
Common Stock
21250
131170
D
The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
Includes 144 shares of common stock acquired under the issuer's employee stock purchase plan in December 2020.
Reflects the transfer of 98,353 shares of common stock previously held directly by the reporting person to Three Colleens Investment, LLC, an entity through which the reporting person holds such shares of common stock indirectly.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.83 to $68.82, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 4 through 8.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.83 to $69.815, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.83 to $70.795, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.99 to $70.985, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.99 to $71.85, inclusive.
Mr. Stack and his wife are the owners of each of Three Colleens Investment, LLC and LCK Investment LLC. Mr. Stack is the general partner of Stack Schroon Mohawk FLP.
The option vested and became exercisable as to 25% of the option shares on June 5, 2013 and as to the remaining shares in successive equal monthly installments for the subsequent 36 months.
/s/ Kristen Williams, Attorney-in-Fact
2021-02-04